5 results about "Fluoreszein" patented technology

This invention relates to a chemiluminescent immunoassay reagent for tacrolimus, its preparation, and detection method. The reagent comprises a first reagent, a second reagent, and a magnetic separation reagent. The first reagent is a buffer solution containing a fluorescein-labeled anti-tacrolimus monoclonal antibody at a pH of 6.0–9.0, with the concentration of the fluorescein-labeled anti-tacrolimus monoclonal antibody being 1.0–5.0 μg / mL. The second reagent is a buffer solution containing a tacrolimus-alkaline phosphatase conjugate at a pH of 6.0–9.0, with the concentration of the tacrolimus-alkaline phosphatase conjugate being 0.05–0.20 μg / mL. The magnetic separation reagent is a suspension of magnetic microparticles coated with the anti-fluorescein monoclonal antibody. This invention enables the quantitative detection of tacrolimus with lower cost and higher accuracy and precision.

The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.

Neuroendocrine tumors (NETs) are a class of highly heterogeneous tumors derived from neuroendocrine cells. Synaptic vesicle 2 (SV2) protein is a novel marker of NETs, and there are three subtypes of SV2A, SV2B and SV2C, wherein the structure of SV2C is more stable than the other two, and the largest cavity ring L4 thereof is the most important binding area with toxins. The present application obtains a nanobody of the extracellular soluble part L4 of SV2 by screening through phage display technology, and the nanobody labeled with a fluorescein, a small molecule of a chemical toxin or a nuclide is used to prepare a probe molecule, and the result can be specifically combined with neuroendocrine tumor cells. The present application provides a nanobody of the extracellular soluble part L4 of SV2, and the nanobody can be applied in the preparation of diagnostic and therapeutic preparations for neuroendocrine tumors.

The application provides an antibody composition for detecting acute T lymphoblastic leukemia by full-spectrum flow cytometry, a detection system and application thereof, and relates to the technical field of blood disease detection. The antibody composition is two groups of antibodies. The first group is 14 kinds of fluorescein-labeled cell membrane monoclonal antibodies, including anti-CD45, anti-CD99, anti-CD34, anti-CD48, anti-CD2, anti-CD3, anti-CD4, anti-CD5, anti-CD7, anti-CD8a, anti-CD16, anti-CD56, anti-CD94 and anti-TCR gamma delta. The second group is two kinds of intracellular monoclonal antibodies, including anti-nucleus TdT and anti-cytoplasm CD3. The two groups of antibodies are added into the same tube in sequence. The application also provides a flow cytometry sample for detecting acute T lymphoblastic leukemia based on full-spectrum flow cytometry, and a detection analysis method and system, so that the missed diagnosis rate and misdiagnosis rate of T-ALL detection are reduced.

This invention relates to the field of nitric oxide donor technology, and particularly to a fluorescein-fused nitric oxide donor, its preparation method, and its application. The method includes the following steps: adding N,N-dimethylformamide to a mixture of an aromatic compound containing a para-active halogenated side chain and potassium carbonate; stirring; adding 3-trifluoromethyl-4-nitroaniline; quenching the reaction with saturated brine; drying and vacuum concentration; and purifying. Then, mixing fluorescein, potassium carbonate, and dimethyl sulfoxide and stirring; placing the first mixture in an ice-water bath; adding a second mixture; quenching the reaction with saturated brine; drying and vacuum concentration; and purifying to obtain the fluorescein-fused nitric oxide donor. This constructs a functional molecule that combines NO release function and fluorescence response characteristics, achieving an integrated release-response-imaging function. This solves the problem that existing NO donors are difficult to monitor in real time, making it impossible to intuitively and in real-time trace NO release behavior, thus limiting the practical application of nitric oxide donors.